**3.5 Transcatheter aortic valve implantation (TAVI), peripheral artery disease, atherosclerosis, and mechanical prosthesis**

Dual antiplatelet therapy is indicated in patients on the line for transcatheter aortic valve implantation (TAVI) without high risk of hemorrhage for 3–6 months [17]. After revascularization, DAPT is usually indicated for 1–12 months in peripheral artery disease (PAD) patients [17]. It is worth to note that DAPT can be extended for more than 1 year in patients with atherosclerosis and mechanical prosthesis having high risk of coronary events [17].

## **3.6 Other indications of DAPT**

DAPT can also be used in other nonconventional indications, which include diabetes, renal transplant, and carotid endarterectomy. In diabetes, DAPT consisting of aspirin and prasugrel or ticagrelor is indicated due to increased platelet reactivity [41]. DAPT administration reduces the risk of cardiovascular events in patients undergoing renal transplant. On the other hand, the risk of postoperative hemorrhage is increased with DAPT. Therefore, DAPT is strictly recommended for renal transplant patients with high risk of cardiovascular events [42]. DAPT can also be used for patients undergoing carotid endarterectomy [34].
